DK1284754T3 - Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration - Google Patents

Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration

Info

Publication number
DK1284754T3
DK1284754T3 DK01929595T DK01929595T DK1284754T3 DK 1284754 T3 DK1284754 T3 DK 1284754T3 DK 01929595 T DK01929595 T DK 01929595T DK 01929595 T DK01929595 T DK 01929595T DK 1284754 T3 DK1284754 T3 DK 1284754T3
Authority
DK
Denmark
Prior art keywords
salts
gel
pharmaceutical composition
subcutaneous administration
biphosphonic acids
Prior art date
Application number
DK01929595T
Other languages
Danish (da)
English (en)
Inventor
Petra Bastian
Rainer Bader
Achim Goepferich
Wolfgang Roedel
Gerhard Winter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1284754T3 publication Critical patent/DK1284754T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01929595T 2000-05-05 2001-04-23 Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration DK1284754T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10021917 2000-05-05

Publications (1)

Publication Number Publication Date
DK1284754T3 true DK1284754T3 (da) 2006-05-01

Family

ID=7640900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01929595T DK1284754T3 (da) 2000-05-05 2001-04-23 Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration

Country Status (16)

Country Link
US (1) US6676970B2 (de)
EP (1) EP1284754B1 (de)
JP (1) JP3923800B2 (de)
KR (1) KR100492110B1 (de)
CN (1) CN1180846C (de)
AR (2) AR033671A1 (de)
AT (1) ATE314862T1 (de)
AU (1) AU778431B2 (de)
BR (1) BR0110618A (de)
CA (1) CA2407747C (de)
DE (1) DE60116483T2 (de)
DK (1) DK1284754T3 (de)
ES (1) ES2254410T3 (de)
MX (1) MXPA02010740A (de)
WO (1) WO2001085217A1 (de)
ZA (1) ZA200208499B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365770A2 (de) * 2001-02-07 2003-12-03 Durect Corporation Vorrichtungen und verfahren zur erhaltung der knochendichte
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
EP1713489B1 (de) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
US7294195B2 (en) * 2005-08-08 2007-11-13 Wacker Chemical Corporation Water repellant gypsum compositions
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
EP1923049A1 (de) * 2006-11-17 2008-05-21 Besins Healthcare Pharmazeutische Zusammensetzungen mit einer Bisphosphonatverbindung
WO2008059059A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP1992364A1 (de) * 2007-05-16 2008-11-19 Biosuma S.r.l. Phosphierte oder bisphosphonierte und optional vernetzte Derivate carboxylierter Polysaccharide sowie ihre Herstellung und ihre biomedizinischen Verwendungen
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20100247607A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
US20120089118A1 (en) * 2010-10-08 2012-04-12 A Nevada Corporation Delivery of bisphosphonates by microinjection systems
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201412236D0 (en) * 2014-07-09 2014-08-20 Univ Nottingham Method of producing and using alginate hydrogels
US10471141B2 (en) * 2014-09-03 2019-11-12 Nitto Denko Corporation Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
IT201800009444A1 (it) 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE61111C (de) B. WINKLER in Berka a. Werrä Verfahren zur Herstellung von Knöpfen ohne Fadenbefestigung
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation

Also Published As

Publication number Publication date
CA2407747A1 (en) 2001-11-15
DE60116483T2 (de) 2006-09-07
KR20030009470A (ko) 2003-01-29
US20010053388A1 (en) 2001-12-20
ES2254410T3 (es) 2006-06-16
AR033671A1 (es) 2004-01-07
ATE314862T1 (de) 2006-02-15
EP1284754A1 (de) 2003-02-26
MXPA02010740A (es) 2003-03-10
CA2407747C (en) 2008-03-11
ZA200208499B (en) 2004-02-26
WO2001085217A1 (en) 2001-11-15
CN1180846C (zh) 2004-12-22
KR100492110B1 (ko) 2005-06-02
CN1427727A (zh) 2003-07-02
AR055407A2 (es) 2007-08-22
JP3923800B2 (ja) 2007-06-06
US6676970B2 (en) 2004-01-13
AU5631701A (en) 2001-11-20
AU778431B2 (en) 2004-12-02
BR0110618A (pt) 2003-04-29
DE60116483D1 (de) 2006-03-30
EP1284754B1 (de) 2006-01-04
JP2003532689A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
DK1284754T3 (da) Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
ATE293119T1 (de) Cardioprotektive phosphonate
EA200400777A1 (ru) Фармацевтические композиции соединения платины
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
DE602006018467D1 (de) Schnell lösliche Formulierung von nichtsteroidalen Antiphlogistika
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
HUP0302050A2 (hu) Peptidek beadására alkalmas gyógyszerforma, eljárás az elżállítására és alkalmazása
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
MXPA05010613A (es) Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo.
NO20064783L (no) Opplosningstabeletter med licarbazepin
CL2008003002A1 (es) Composición farmacéutica inyectable intravenosa en forma de emulsión aceite en agua que comprende al toxoide larotaxel (xrp9881) o cabazitaxel (xrp6258) disuelto en lecitina, y al tensioactivo aniónico fosfatidilglicerol o acido fosfatidico; proeceidimiento para su preparacion, útil como antineoplástico.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
WO2009087682A3 (en) Stabilized injectable formulation of pregabalin
EA200501252A1 (ru) Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
EA200600070A1 (ru) Инъецируемая галеновая форма флупиртина